Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Show more
Location: 245 Main Street, Cambridge, MA, 02142, United States | Website: https://immuneering.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
386.4M
52 Wk Range
$1.10 - $10.08
Previous Close
$6.11
Open
$6.14
Volume
877,274
Day Range
$6.13 - $6.45
Enterprise Value
390.6M
Cash
26.36M
Avg Qtr Burn
-12.88M
Insider Ownership
15.25%
Institutional Own.
12.99%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IMM-1-104 + Libtayo Details Cancer, Non-small cell lung carcinoma | Phase 2a Data readout | |
Atebimetinib (IMM-1-104) Details 1L Pancreatic cancer | Phase 2a Update | |
IMM-1-104 + G12C inhibitor Details Cancer, Non-small cell lung carcinoma | Phase 2a Initiation | |
IMM-1-104 + PD-1 inhibitor Details Cancer, Melanoma | Phase 2a Initiation | |
IMM-1-104 + BRAF inhibitor Details Cancer, Melanoma | Phase 2a Initiation | |
IMM-6-415 Details Solid tumor/s | Phase 1/2 Update |